既往消融治疗后肺部立体定向体部放射治疗：单机构病例系列
Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series.
作者信息
Wegner Rodney E, Ahmed Nissar, Hasan Shaakir, Schumacher Lana Y, Colonias Athanasios
机构信息
Division of Radiation Oncology, Allegheny Health Network Cancer Institute, 320 E North Ave, Pittsburgh, PA 15212, USA.
Allegheny Health Network Esophagus & Lung Institute, 320 E North Ave, Pittsburgh, PA 15212, USA.
出版信息
Lung Cancer Manag. 2018 Dec 21;7(3):LMT05. doi: 10.2217/lmt-2018-0012. eCollection 2018 Nov.
AIM
Non-small-cell lung cancer recurs locally 10-40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients.
METHODS
We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy.
RESULTS
Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT.
CONCLUSION
SBRT is safe and effective when used for re-irradiation after past ablative therapies.
目的
非小细胞肺癌在局部治疗后有10% - 40%的概率会出现局部复发，鉴于肺部储备功能较差，这带来了治疗挑战。在此，我们旨在评估立体定向体部放疗（SBRT）对这类患者进行再治疗的安全性和有效性。
方法
我们确定并回顾了10例既往接受过 Vicryl 网片近距离放疗后复发的非小细胞肺癌患者的临床结局。
结果
10例患者的中位年龄为77岁，接受了中位剂量为48 Gy、分5次的治疗。1年时的局部控制率为88%。在29个月时出现1例远处转移。SBRT后无明显毒性反应。
结论
SBRT用于既往消融治疗后的再照射时是安全有效的。
Zotero 插件